Reta glucagon-like peptide-1 (GLP-1) receptor agonists provide a groundbreaking strategy to diabetes management. These innovative drugs work by mimicking the physiological actions of GLP-1, a hormone secreted by the gut in response to consumption. By triggering GLP-1 receptors in the pancreas, these substances enhance insulin production and reduce

The burgeoning landscape of emerging treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a comparable therapeutic goal – improving glycemic control and promoting considerable weight loss – they exhibit intriguing variations i